These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 26900075)
21. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Reardon DA; Wen PY Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836 [TBL] [Abstract][Full Text] [Related]
22. Therapy for glioblastoma: is it working? Zanders ED; Svensson F; Bailey DS Drug Discov Today; 2019 May; 24(5):1193-1201. PubMed ID: 30878561 [TBL] [Abstract][Full Text] [Related]
23. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
25. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
26. Glioblastoma: from molecular pathology to targeted treatment. Cloughesy TF; Cavenee WK; Mischel PS Annu Rev Pathol; 2014; 9():1-25. PubMed ID: 23937436 [TBL] [Abstract][Full Text] [Related]
27. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. Venkatesan S; Lamfers ML; Dirven CM; Leenstra S CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934 [TBL] [Abstract][Full Text] [Related]
28. Incorporation of biomarkers in phase II studies of recurrent glioblastoma. Jue TR; Hovey E; Davis S; Carleton O; McDonald KL Tumour Biol; 2015 Jan; 36(1):153-62. PubMed ID: 25534238 [TBL] [Abstract][Full Text] [Related]
29. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Wu W; Klockow JL; Zhang M; Lafortune F; Chang E; Jin L; Wu Y; Daldrup-Link HE Pharmacol Res; 2021 Sep; 171():105780. PubMed ID: 34302977 [TBL] [Abstract][Full Text] [Related]
30. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
31. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma. Zhang N; Wei L; Ye M; Kang C; You H Front Immunol; 2020; 11():592612. PubMed ID: 33329578 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200 [TBL] [Abstract][Full Text] [Related]
33. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Ning S; Knox SJ Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556 [TBL] [Abstract][Full Text] [Related]
34. Molecular neuro-oncology and the challenge of the blood-brain barrier. Aiken R Semin Oncol; 2014 Aug; 41(4):438-445. PubMed ID: 25173137 [TBL] [Abstract][Full Text] [Related]
35. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996 [TBL] [Abstract][Full Text] [Related]